Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17979926 | 0.89 | CTSB (0.71) | CTSBALDH1A1KCNJ1MAPTLMNA | |
| SCHEMBL9609632 | 0.87 | ALDH1A1 (0.51) | CTSBALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL2573993 | 0.84 | KMT2A (0.53) | CTSBALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL19500738 | 0.84 | CDK1 (0.49) | CTSBALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL23213827 | 0.83 | CTSB (0.60) | CTSBALDH1A1KCNJ1MAPTLMNA | |
| SCHEMBL923179 | 0.83 | CTSB (0.67) | CTSBALDH1A1KCNJ1MAPTLMNA | |
| SCHEMBL29716254 | 0.83 | CTSB (0.60) | CTSBALDH1A1KCNJ1MAPTLMNA | |
| SCHEMBL18491687 | 0.83 | CTSB (0.67) | CTSBALDH1A1KCNJ1MAPTLMNA | |
| SCHEMBL4269241 | 0.83 | KCNJ1 (0.74) | CTSBALDH1A1KCNJ1MAPTLMNA | |
| SCHEMBL521635 | 0.81 | LMNA (0.71) | CTSBALDH1A1KCNJ1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | disclosed |
| CN-101516860-B | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG | 2012-06-27 | — | — | CN | disclosed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| CN-101516860-A | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2066647-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031594-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | JAK2, JAK3, JAK1 | CTSB 4682/4885ALDH1A1 1245/4885KCNJ1 1859/4885 |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | CDK19, CDK9, CDK8 | CTSB 3822/4885ALDH1A1 3859/4885KCNJ1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.